Pharmaceutical Executive
Although still tightly regulated, healthcare industry stakeholders-buoyed by regulatory reforms aimed at increasing patient access to innovative new therapies-are cautiously optimistic that the Czech Republic will further close the gap with Western Europe.
Although dwarfed in size by some of the biggest economies in Europe with which it shares its borders, the Czech Republic is one of the Central and Eastern European (CEE) region’s best-performing economies. Indeed, on a per capita level, the Czechs are well ahead of their CEE neighbors, with GDP (PPP) per capita standing at USD 39,337 in 2019.
Moreover, the Czechs can proudly boast one of the best healthcare systems in the CEE; despite healthcare expenditure as a percentage of GDP standing at 7.2% compared to an EU average of 9.8%. A universal healthcare system funded by seven insurance companies covers the healthcare needs of the vast majority of the country’s 10 million citizens. The Czech healthcare system is “slowly progressing and converging with Western standards,” says Janssen’s managing director, Martin MinaroviÄ. Minister of Health Adam VojtÄch agrees, stating that, “we are comparable to all EU members and can serve as an example to countries in the East."
Against this backdrop stands a USD 3.38 billion domestic pharmaceutical market buoyed by regulatory reforms aimed at increasing patient access to innovative new therapies. Although still tightly regulated, industry stakeholders are cautiously optimistic that the Czech Republic stands to further close the gap with Western Europe.
To view the full article on the Czech Republic’s life sciences and healthcare markets, produced by Focus Reports and featured in Pharm Exec's April 2020 issue, click
here(cycle down to page 32).
To preview and purchase other in-depth global Phama Reports, highlighting several countries and emerging markets, please visit www.industrymatter.com/reports
Young & Partners Pharmaceutical Executive Summit 2024: Brave New World – Where Are We Heading?
October 23rd 2024Peter Marks, director, Center for Biologics Evaluation and Research, FDA, presented the keynote presentation on the future of gene therapy as part of the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.